🚀 VC round data is live in beta, check it out!
Biotest Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biotest and similar public comparables like Marksans Pharma, Gyre Therapeutics, Basilea Pharmaceutica, Strides Pharma and more.
Biotest Overview
About Biotest
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The company covers preclinical and clinical development of the preparations, plasma collection, production, as well as marketing and sales.
Founded
1946
HQ
Employees
2.7K
Website
Financials (FY)
EV
$1B
Biotest Financials
Biotest reported last fiscal year revenue of $839M and EBITDA of $139M.
In the same fiscal year, Biotest generated $258M in gross profit, $139M in EBITDA, and $30M in net income.
Biotest P&L
In the most recent fiscal year, Biotest reported revenue of $839M and EBITDA of $139M.
Biotest expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $839M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $258M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 31% | XXX | XXX | XXX |
| EBITDA | — | XXX | $139M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 12% | XXX | XXX | XXX |
| Net Profit | — | XXX | $30M | XXX | XXX | XXX |
| Net Margin | — | XXX | 4% | XXX | XXX | XXX |
| Net Debt | — | — | $498M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Biotest Stock Performance
Biotest has current market cap of $841M, and enterprise value of $1B.
Biotest's stock price is $21.25.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $841M | 0.1% | XXX | XXX | XXX | $0.77 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiotest Valuation Multiples
Biotest trades at 1.7x EV/Revenue multiple, and 10.0x EV/EBITDA.
Biotest Financial Valuation Multiples
As of March 29, 2026, Biotest has market cap of $841M and EV of $1B.
Equity research analysts estimate Biotest's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biotest has a P/E ratio of 27.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $841M | XXX | $841M | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 10.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 14.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.4x | XXX | XXX | XXX |
| P/E | — | XXX | 27.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 37.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biotest Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Biotest Margins & Growth Rates
Biotest's revenue in the last fiscal year grew by 6%.
Biotest Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (34%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Biotest Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Bioindustrials comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Marksans Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Gyre Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Basilea Pharmaceutica | XXX | XXX | XXX | XXX | XXX | XXX |
| Strides Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| OPKO Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biotest M&A Activity
Biotest acquired XXX companies to date.
Last acquisition by Biotest was on XXXXXXXX, XXXXX. Biotest acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Biotest
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBiotest Investment Activity
Biotest invested in XXX companies to date.
Biotest made its latest investment on XXXXXXXX, XXXXX. Biotest invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Biotest
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biotest
| When was Biotest founded? | Biotest was founded in 1946. |
| Where is Biotest headquartered? | Biotest is headquartered in Germany. |
| How many employees does Biotest have? | As of today, Biotest has over 2K employees. |
| Is Biotest publicly listed? | Yes, Biotest is a public company listed on Hamburg Stock Exchange. |
| What is the stock symbol of Biotest? | Biotest trades under BIO ticker. |
| When did Biotest go public? | Biotest went public in 1999. |
| Who are competitors of Biotest? | Biotest main competitors are Marksans Pharma, Gyre Therapeutics, Basilea Pharmaceutica, Strides Pharma. |
| What is the current market cap of Biotest? | Biotest's current market cap is $841M. |
| What is the current revenue of Biotest? | Biotest's last fiscal year revenue is $839M. |
| What is the current EV/Revenue multiple of Biotest? | Current revenue multiple of Biotest is 1.7x. |
| Is Biotest profitable? | No, Biotest is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.